Ozempic vs Mounjaro: does the stronger drug always win?

What did @doctormaloney actually say?

The doctor argued that tirzepatide produces stronger weight loss results than semaglutide, but that stronger isn't always better. The core claim: people who lose weight purely through appetite suppression struggle most after stopping the medication. Therefore, semaglutide's relatively weaker effect might actually set patients up for better long-term outcomes. He also pushed diet as the foundation, before, during, and after any medication.

It's a refreshingly honest framing for a GLP-1 video. He's not selling you on the strongest drug. He's raising a real clinical tension that most promotional content completely ignores: what happens when you stop?

Does the science back this up?

The superiority of tirzepatide over semaglutide for weight loss is well-supported. The SURMOUNT-5 trial (Jastreboff et al., 2025, NEJM) directly compared the two in adults with obesity and no diabetes. Tirzepatide produced roughly 20.2% body weight reduction versus 13.7% for semaglutide over 72 weeks. That gap is clinically meaningful, not statistical noise.

The dependency and rebound claim is trickier. The STEP 1 extension study (Wilding et al., 2022, Diabetes, Obesity and Metabolism) showed that participants regained about two-thirds of their lost weight within a year of stopping semaglutide. Similar rebound data exists for tirzepatide. What the science hasn't cleanly established is whether the degree of appetite suppression during treatment predicts how badly someone rebounds after stopping. That specific mechanistic link, stronger drug equals harder withdrawal, is largely the doctor's clinical opinion, not a randomized finding.

What did they get wrong (or right)?

He got the efficacy hierarchy right. Tirzepatide's dual GIP and GLP-1 agonism does produce meaningfully greater weight loss in head-to-head data. Credit where it's due.

Where things get shakier is the dependency framing. Calling appetite suppression a kind of dependency that makes stopping harder is intuitive, but it applies to both drugs. There's no published trial showing semaglutide patients transition off medication more successfully than tirzepatide patients because of the potency difference. The rebound phenomenon appears to be a class effect tied to GLP-1 receptor agonism broadly, not a tirzepatide-specific trap. Saying tirzepatide might leave patients more "dependent" without evidence for that comparative claim is speculative.

His point about diet leading the way is correct and underappreciated. Behavioral change alongside medication is associated with better maintenance outcomes (Wadden et al., 2020, Obesity).

What should you actually know?

Both drugs work. Both carry significant rebound risk when stopped. The choice between semaglutide and tirzepatide should be driven by your metabolic profile, side effect tolerance, cardiovascular history, insurance coverage, and what you can actually sustain, not by a TikTok preference for "not too strong."

The doctor's instinct to avoid maximizing appetite suppression for its own sake isn't wrong as a philosophy. Minimum effective dose is a reasonable clinical principle. But presenting semaglutide's lower potency as a feature rather than simply a characteristic oversimplifies the decision. Some patients need the stronger effect to achieve metabolically meaningful weight loss, and under-treating obesity carries its own serious risks.

• Weight regain after stopping either medication is well-documented and is not unique to tirzepatide.
• Lifestyle intervention quality during treatment likely matters more for long-term outcomes than which drug you picked.
• No published comparative data shows semaglutide patients maintain weight better post-discontinuation than tirzepatide patients.

Should you follow this advice?

The diet-first framing is solid and worth keeping. The comparative preference for semaglutide based on dependency risk is a clinical opinion without strong evidentiary backing. It may be reasonable for specific patients in specific situations, but it's not a general rule the research currently supports. Talk to a physician who knows your full history before choosing between these medications based on a 60-second video, even one from an actual doctor.